As expected, the phosphorylation of MEK and Akt was inhibited in the same manner as that of EGFR and c-MET, suggesting that ψ-Bufarenogin suppresses HCC progression via the inhibition of EGFR and c-MET-mediated signaling (Figure 6C). This evidence concerns the gene AKT1 and hepatocellular carcinoma.